A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease

Marvin E. Reid, Amal El Beshlawy, Adlette Inati, Abdullah Kutlar, Miguel R. Abboud, Johnson Haynes, Richard Ward, Bruce Sharon, Ali T. Taher, Wally Smith, Deepa Manwani, Richard G. Ghalie

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

This placebo-controlled phase II study evaluated the pharmacodynamics, efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), a fetal globin gene-inducing short-chain fatty acid derivative, administered orally at 15 mg/kg twice daily for 48 weeks in 76 subjects with sickle cell disease (SCD). The median age was 26 years (range: 12-55 years) and 37 subjects (49%) were treated previously with hydroxycarbamide. Sixty subjects (79%) had Hb SS and 16 (21%) had S/β0 thalassemia. The study was terminated after a planned interim analysis showed no significant increase in fetal hemoglobin (Hb F) and a trend for more pain crises in the HQK-1001 group. For 54 subjects with Week 24 data, the mean absolute increase in Hb F was 0.9% (95% confidence interval (CI): 0.1-1.6%) with HQK-1001 and 0.2% (95% CI: -0.7-1.1%) with placebo. Absolute increases in Hb F greater than 3% were noted in 9 of 38 subjects (24%) administered HQK-1001 and 1 of 38 subjects (3%) administered placebo. The mean changes in hemoglobin at Week 24 were comparable between the two groups. The mean annualized rate of pain crises was 3.5 with HQK-1001 and 1.7 with placebo. The most common adverse events in the HQK-1001 group, usually graded as mild or moderate, consisted of nausea, headache, vomiting, abdominal pain, and fatigue. Additional studies of HQK-1001 at this dose and schedule are not recommended in SCD. Intermittent HQK-1001 administration, rather than a daily regimen, may be better tolerated and more effective, as shown previously with arginine butyrate, and warrants further evaluation. Am. J. Hematol. 89:709-713, 2014.

Original languageEnglish (US)
Pages (from-to)709-713
Number of pages5
JournalAmerican Journal of Hematology
Volume89
Issue number7
DOIs
StatePublished - Jan 1 2014

Fingerprint

2,2-dimethylbutyric acid
Globins
Sickle Cell Anemia
Placebos
Safety
Fetal Hemoglobin
Confidence Intervals
Pain
Thalassemia
Volatile Fatty Acids

ASJC Scopus subject areas

  • Hematology

Cite this

A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. / Reid, Marvin E.; El Beshlawy, Amal; Inati, Adlette; Kutlar, Abdullah; Abboud, Miguel R.; Haynes, Johnson; Ward, Richard; Sharon, Bruce; Taher, Ali T.; Smith, Wally; Manwani, Deepa; Ghalie, Richard G.

In: American Journal of Hematology, Vol. 89, No. 7, 01.01.2014, p. 709-713.

Research output: Contribution to journalArticle

Reid, ME, El Beshlawy, A, Inati, A, Kutlar, A, Abboud, MR, Haynes, J, Ward, R, Sharon, B, Taher, AT, Smith, W, Manwani, D & Ghalie, RG 2014, 'A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease', American Journal of Hematology, vol. 89, no. 7, pp. 709-713. https://doi.org/10.1002/ajh.23725
Reid, Marvin E. ; El Beshlawy, Amal ; Inati, Adlette ; Kutlar, Abdullah ; Abboud, Miguel R. ; Haynes, Johnson ; Ward, Richard ; Sharon, Bruce ; Taher, Ali T. ; Smith, Wally ; Manwani, Deepa ; Ghalie, Richard G. / A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. In: American Journal of Hematology. 2014 ; Vol. 89, No. 7. pp. 709-713.
@article{e22872bd10a649828e497cd646bd46d4,
title = "A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease",
abstract = "This placebo-controlled phase II study evaluated the pharmacodynamics, efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), a fetal globin gene-inducing short-chain fatty acid derivative, administered orally at 15 mg/kg twice daily for 48 weeks in 76 subjects with sickle cell disease (SCD). The median age was 26 years (range: 12-55 years) and 37 subjects (49{\%}) were treated previously with hydroxycarbamide. Sixty subjects (79{\%}) had Hb SS and 16 (21{\%}) had S/β0 thalassemia. The study was terminated after a planned interim analysis showed no significant increase in fetal hemoglobin (Hb F) and a trend for more pain crises in the HQK-1001 group. For 54 subjects with Week 24 data, the mean absolute increase in Hb F was 0.9{\%} (95{\%} confidence interval (CI): 0.1-1.6{\%}) with HQK-1001 and 0.2{\%} (95{\%} CI: -0.7-1.1{\%}) with placebo. Absolute increases in Hb F greater than 3{\%} were noted in 9 of 38 subjects (24{\%}) administered HQK-1001 and 1 of 38 subjects (3{\%}) administered placebo. The mean changes in hemoglobin at Week 24 were comparable between the two groups. The mean annualized rate of pain crises was 3.5 with HQK-1001 and 1.7 with placebo. The most common adverse events in the HQK-1001 group, usually graded as mild or moderate, consisted of nausea, headache, vomiting, abdominal pain, and fatigue. Additional studies of HQK-1001 at this dose and schedule are not recommended in SCD. Intermittent HQK-1001 administration, rather than a daily regimen, may be better tolerated and more effective, as shown previously with arginine butyrate, and warrants further evaluation. Am. J. Hematol. 89:709-713, 2014.",
author = "Reid, {Marvin E.} and {El Beshlawy}, Amal and Adlette Inati and Abdullah Kutlar and Abboud, {Miguel R.} and Johnson Haynes and Richard Ward and Bruce Sharon and Taher, {Ali T.} and Wally Smith and Deepa Manwani and Ghalie, {Richard G.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/ajh.23725",
language = "English (US)",
volume = "89",
pages = "709--713",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease

AU - Reid, Marvin E.

AU - El Beshlawy, Amal

AU - Inati, Adlette

AU - Kutlar, Abdullah

AU - Abboud, Miguel R.

AU - Haynes, Johnson

AU - Ward, Richard

AU - Sharon, Bruce

AU - Taher, Ali T.

AU - Smith, Wally

AU - Manwani, Deepa

AU - Ghalie, Richard G.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - This placebo-controlled phase II study evaluated the pharmacodynamics, efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), a fetal globin gene-inducing short-chain fatty acid derivative, administered orally at 15 mg/kg twice daily for 48 weeks in 76 subjects with sickle cell disease (SCD). The median age was 26 years (range: 12-55 years) and 37 subjects (49%) were treated previously with hydroxycarbamide. Sixty subjects (79%) had Hb SS and 16 (21%) had S/β0 thalassemia. The study was terminated after a planned interim analysis showed no significant increase in fetal hemoglobin (Hb F) and a trend for more pain crises in the HQK-1001 group. For 54 subjects with Week 24 data, the mean absolute increase in Hb F was 0.9% (95% confidence interval (CI): 0.1-1.6%) with HQK-1001 and 0.2% (95% CI: -0.7-1.1%) with placebo. Absolute increases in Hb F greater than 3% were noted in 9 of 38 subjects (24%) administered HQK-1001 and 1 of 38 subjects (3%) administered placebo. The mean changes in hemoglobin at Week 24 were comparable between the two groups. The mean annualized rate of pain crises was 3.5 with HQK-1001 and 1.7 with placebo. The most common adverse events in the HQK-1001 group, usually graded as mild or moderate, consisted of nausea, headache, vomiting, abdominal pain, and fatigue. Additional studies of HQK-1001 at this dose and schedule are not recommended in SCD. Intermittent HQK-1001 administration, rather than a daily regimen, may be better tolerated and more effective, as shown previously with arginine butyrate, and warrants further evaluation. Am. J. Hematol. 89:709-713, 2014.

AB - This placebo-controlled phase II study evaluated the pharmacodynamics, efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), a fetal globin gene-inducing short-chain fatty acid derivative, administered orally at 15 mg/kg twice daily for 48 weeks in 76 subjects with sickle cell disease (SCD). The median age was 26 years (range: 12-55 years) and 37 subjects (49%) were treated previously with hydroxycarbamide. Sixty subjects (79%) had Hb SS and 16 (21%) had S/β0 thalassemia. The study was terminated after a planned interim analysis showed no significant increase in fetal hemoglobin (Hb F) and a trend for more pain crises in the HQK-1001 group. For 54 subjects with Week 24 data, the mean absolute increase in Hb F was 0.9% (95% confidence interval (CI): 0.1-1.6%) with HQK-1001 and 0.2% (95% CI: -0.7-1.1%) with placebo. Absolute increases in Hb F greater than 3% were noted in 9 of 38 subjects (24%) administered HQK-1001 and 1 of 38 subjects (3%) administered placebo. The mean changes in hemoglobin at Week 24 were comparable between the two groups. The mean annualized rate of pain crises was 3.5 with HQK-1001 and 1.7 with placebo. The most common adverse events in the HQK-1001 group, usually graded as mild or moderate, consisted of nausea, headache, vomiting, abdominal pain, and fatigue. Additional studies of HQK-1001 at this dose and schedule are not recommended in SCD. Intermittent HQK-1001 administration, rather than a daily regimen, may be better tolerated and more effective, as shown previously with arginine butyrate, and warrants further evaluation. Am. J. Hematol. 89:709-713, 2014.

UR - http://www.scopus.com/inward/record.url?scp=84902827324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902827324&partnerID=8YFLogxK

U2 - 10.1002/ajh.23725

DO - 10.1002/ajh.23725

M3 - Article

C2 - 24677033

AN - SCOPUS:84902827324

VL - 89

SP - 709

EP - 713

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -